

Press release
Gothenburg, Sweden
May 14, 2020. 14:15. CET

CELLINK announces collaboration with AstraZeneca to utilize CELLINKs' 3D-bioprinting technology for liver organoid culture

CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.

In tissue engineering, the need for assembly of three-dimensional (3D) tissues is important. 3D-bioprinting has emerged as a useful technology to recapitulate the microenvironment of native tissue, allowing for precise printing of multiple cells into a pre-defined position.

CELLINK has an R&D lab in AstraZeneca's BioVentureHub in Gothenburg, Sweden. The new collaboration will leverage CELLINK's innovative and patent-pending bioink, Extra Cellular Matrix and Laminin based bioinks, which enables human cells to grow and function as they would in the human body.

For further information, please contact:

Erik Gatenholm, CEO

Phone (Sweden): +46 73 267 00 00

Phone (US): +1 (650) 515 5566

Email: eg@cellink.com

Gusten Danielsson, CFO

Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (857) 332 2138

Email: gd@cellink.com

About CELLINK

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.